Jay Clemens
IBM Corp. has moved to expand the cognitive offerings of its Watson supercomputer by partnering with Baylor College of Medicine, Johnson & Johnson, Sanofi and New York Genome Center on several big data research projects.
Researchers will work to accelerate discoveries, test hypotheses and draw conclusions by using IBM’s Watson Discovery Advisor tool, IBM said Thursday.
“We’re empowering researchers with a powerful tool which will help increase the impact of investments organizations make in R&D, leading to significant breakthroughs,†said Mike Rhodin, senior vice president of IBM’s Watson Group.
Scientists used the Watson-based Baylor Knowledge Integration toolkit to identify proteins that could alter the p53 protein related to different cancers and the team plans to conduct further research on cancer medicines and treatments.
IBM is also working with Johnson & Johnson to direct the Watson cognitive computing system to analyze clinical trial outcomes from scientific papers in order to develop medications and treatments.
New York Genome Center is analyzing its genomic medicine study with IBM Watson and Sanofi is using the tool to explore alternate indications for existing drugs.
